Korea Cardiovascular Stent Research Institute of Chonnam National University, Gwangju, Korea.
Korean Circ J. 2013 Oct;43(10):645-54. doi: 10.4070/kcj.2013.43.10.645.
Restenosis and stent thrombosis remain major concerns after percutaneous coronary intervention for the treatment of coronary artery disease. The present review was undertaken in order to highlight the various coronary stents that have been investigated in our Heart Research Center, and how far we have come from the first heparin-coated stent first used in the late 1990s. Thereafter, from the abciximab-coated stent to the current gene-delivery stent and other newer agents, our group has applied a range of techniques in this field. However, in groups similar to ours, the restenosis rates of such stents are still high for second-generation drug-eluting stents (DESs). Moreover, our nation imports almost all of these types of stents from other countries. Thus, we need to develop domestic coronary stents. Research into newer DESs are warranted in Korea so as to achieve improved safety and efficacy outcomes.
经皮冠状动脉介入治疗冠心病后，再狭窄和支架血栓仍然是主要关注点。本综述旨在强调我们心脏研究中心研究过的各种冠状动脉支架，以及从 20 世纪 90 年代末首次使用的肝素涂层支架到目前的基因输送支架和其他新型药物一路走来我们走了多远。此后，从阿昔单抗涂层支架到目前的基因输送支架和其他新型药物，我们的研究小组在该领域应用了一系列技术。然而，在与我们类似的研究小组中，第二代药物洗脱支架 (DES) 的支架内再狭窄率仍然很高。此外，我们国家几乎从其他国家进口所有这些类型的支架。因此，我们需要开发国产冠状动脉支架。韩国有必要对新型 DES 进行研究，以实现更好的安全性和疗效。
